Evidence map›Paper›PMID 37849399›Full record

ArticleThe Journal of infectious diseases2023

Developing a Prototype Pathogen Plan and Research Priorities for the Alphaviruses.

Ann M Powers, Lauren E Williamson, Robert H Carnahan, James E Crowe, Jennifer L Hyde, Colleen B Jonsson, Farooq Nasar, Scott C Weaver

Open access · hybridAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Viral Prototypes for Pandemic Preparedness: The Road Ahead.The Journal of infectious diseases · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Ann M PowersDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.ORCID 0000-0003-2653-7642
Lauren E WilliamsonThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Robert H CarnahanThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
James E CroweThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jennifer L HydeDepartment of Microbiology, University of Washington, Seattle, Washington, USA.
Colleen B JonssonDepartment of Microbiology, Immunology and Biochemistry, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Farooq NasarEmerging Infectious Diseases Branch and Viral Disease Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Scott C WeaverDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Vanderbilt University Medical Center · USCenters for Disease Control and Prevention · USHenry M. Jackson Foundation · USThe University of Texas Medical Branch at Galveston · USUniversity of Tennessee Health Science Center · USUniversity of Washington · USVanderbilt University · US

Funding

Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target EngagementU19AI142762 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CHUNG, DONGHOON · 2019 to 2023
$22.0M
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
NIAID NIH HHS R24 AI120942NIAID NIH HHS U19 AI142762
6 · The paper itself

Abstract

The Togaviridae family, genus, Alphavirus, includes several mosquito-borne human pathogens with the potential to spread to near pandemic proportions. Most of these are zoonotic, with spillover infections of humans and domestic animals, but a few such as chikungunya virus (CHIKV) have the ability to use humans as amplification hosts for transmission in urban settings and explosive outbreaks. Most alphaviruses cause nonspecific acute febrile illness, with pathogenesis sometimes leading to either encephalitis or arthralgic manifestations with severe and chronic morbidity and occasional mortality. The development of countermeasures, especially against CHIKV and Venezuelan equine encephalitis virus that are major threats, has included vaccines and antibody-based therapeutics that are likely to also be successful for rapid responses with other members of the family. However, further work with these prototypes and other alphavirus pathogens should target better understanding of human tropism and pathogenesis, more comprehensive identification of cellular receptors and entry, and better understanding of structural mechanisms of neutralization.

Indexed as

Chikungunya virusCulicidaeAnimalsHorsesHumansResearchAlphavirusprototype pathogenTogaviridae

Identifiers

PMID37849399
PMCPMC11007399
OpenAlexW4387729052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.